Scientific research, clinical trials and evidence base
12 articles
Berberine is called nature's Ozempic, but meta-analyses show only 2 kg weight loss versus 15% on semaglutide. We break down the mechanisms, dosing, and honest data.
What research really shows about berberine, natural GLP-1 boosters, and weight loss supplements. Comparing with the proven efficacy of Ozempic and Mounjaro.
The EMBRAZE 2026 study showed: apitegromab preserves 54.9% more muscle mass during weight loss on tirzepatide. What this means for Mounjaro and Ozempic users.
CagriSema combines semaglutide with amylin and shows 22.7% weight loss. But will it beat tirzepatide? We analyze the REDEFINE and REIMAGINE results.
Orforglipron was approved by the FDA in April 2026. We compare it with Mounjaro and Ozempic: effectiveness 12.4% vs 22.5%, side effects, and when it will be available in Ukraine.
Epitalon is a tetrapeptide Ala-Glu-Asp-Gly from Khavinson's school that activates telomerase. Anisimov 2006: +25-50% mice lifespan extension. 10-day protocol, limitations, synergy.
Ready to lose weight with Mounjaro?
Free specialist consultation — we'll select the right dose and program for you
NMN increases NAD+ by 29% in 8 weeks. Harvard research, 500-1000 mg protocol, comparison with NR and injections. What actually works for anti-aging.
Cagrilintide (Amylin) is a long-acting analog of the amylin hormone. It works through a different pathway than Ozempic or Mounjaro. CagriSema showed -22.7% weight loss over 68 weeks.
What to expect on Retatrutide, side effect profile, and how the triple mechanism changes the experience compared to Mounjaro and Ozempic.
The first drug to activate three receptors simultaneously: GLP-1, GIP, and glucagon. Minus 28.3% weight over 80 weeks in Phase 3 TRIUMPH-1 — but should you start with this one?
GLP-1 pipeline full of innovations: orforglipron, survodutide, amycretin, CagriSema. Understanding when they'll arrive and why you shouldn't wait for the 'perfect' drug.
Anastasiia Shapoval
What do people really lose on Mounjaro and Ozempic? Analysis of clinical data, verified DOZA client cases, and current Retatrutide research. No promises — just numbers.
Anastasiia Shapoval